// App-Quantinova.ai

PB1569 : COASTAL: A PHASE 3 STUDY OF THE PI3KΔ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN’S LYMPHOMA (INHL)

Researchers

Presenter

  • Wojciech Jurczak

Principal Investigators

  • Pier Luigi Zinzani

  • David Cunningham

  • Sharon Yavrom

  • Wenying Huang

  • Igor Gorbatchevsky

  • Vincent Ribrag

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Institut Gustave-Roussy, Villejuif, France

  • MEI Pharma, Inc.,San Diego,United States

  • Institute of Hematology, University of Bologna, Bologna, Italy

Locations

  • United Kingdom

  • Poland

  • France

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03768505

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved